Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) CFO Pete A. Meyers bought 350 shares of Eagle Pharmaceuticals stock in a transaction on Wednesday, August 16th. The shares were purchased at an average cost of $55.45 per share, for a total transaction of $19,407.50. Following the acquisition, the chief financial officer now owns 700 shares in the company, valued at $38,815. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) traded up 3.09% on Wednesday, reaching $55.77. The company’s stock had a trading volume of 324,393 shares. The stock’s 50 day moving average is $65.15 and its 200-day moving average is $75.86. Eagle Pharmaceuticals, Inc. has a 52 week low of $45.05 and a 52 week high of $97.15. The firm has a market capitalization of $845.98 million, a PE ratio of 9.36 and a beta of 1.31.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by $0.18. Eagle Pharmaceuticals had a return on equity of 66.30% and a net margin of 39.32%. The firm had revenue of $50.10 million for the quarter, compared to analyst estimates of $52.52 million. During the same period last year, the business earned $0.80 earnings per share. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. Analysts predict that Eagle Pharmaceuticals, Inc. will post $3.61 EPS for the current year.

Eagle Pharmaceuticals announced that its board has authorized a share repurchase program on Wednesday, August 9th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the specialty pharmaceutical company to repurchase up to 13.3% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/16/eagle-pharmaceuticals-inc-egrx-cfo-purchases-19407-50-in-stock.html.

A number of large investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Eagle Pharmaceuticals during the fourth quarter worth $5,634,000. Teachers Advisors LLC increased its stake in Eagle Pharmaceuticals by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 15,537 shares of the specialty pharmaceutical company’s stock worth $1,233,000 after buying an additional 752 shares during the period. Louisiana State Employees Retirement System increased its stake in Eagle Pharmaceuticals by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 3,300 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 100 shares during the period. Rice Hall James & Associates LLC purchased a new stake in Eagle Pharmaceuticals during the first quarter worth $10,842,000. Finally, Fisher Asset Management LLC increased its stake in Eagle Pharmaceuticals by 32.9% in the first quarter. Fisher Asset Management LLC now owns 7,680 shares of the specialty pharmaceutical company’s stock worth $637,000 after buying an additional 1,900 shares during the period.

A number of research firms have commented on EGRX. BidaskClub raised Eagle Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Piper Jaffray Companies set a $75.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. ValuEngine downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 31st. Finally, Royal Bank Of Canada reduced their target price on Eagle Pharmaceuticals from $94.00 to $81.00 and set an “outperform” rating on the stock in a report on Thursday, July 27th. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $75.40.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.